In 2017, Jiang and co-authors examined the use of anti-GPC3 CAR-T cells in mouse xenograft models, and confirmed that GPC-3-CAR T-cell therapy is a promising candidate for the treatment of HCC [106]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.